BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test sale cost 2200 AED
Prenatal Diagnostic Screening by Karyotyping Test sale cost 2400 AED Prenatal Diagnostic Screening by Karyotyping Test Cost 3,200 د.إ Original price was: 3,200 د.إ.2,400 د.إCurrent price is: 2,400 د.إ.
AML Panel DeletionDuplication Detection Test sale cost 2100 AED AML Panel DeletionDuplication Detection Test Cost 2,800 د.إ Original price was: 2,800 د.إ.2,100 د.إCurrent price is: 2,100 د.إ.
Sale!

BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test Cost

Original price was: 3,000 د.إ.Current price is: 2,200 د.إ.

-27%

The BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test is a highly specialized diagnostic procedure offered by DNA Labs UAE, designed to detect mutations within the kinase domain of the BCR-ABL1 gene. This gene is significant because its mutations are closely associated with chronic myeloid leukemia (CML) and some forms of acute lymphoblastic leukemia (ALL). The presence and type of mutations can influence the patient’s response to tyrosine kinase inhibitors (TKIs), which are a class of medications used in the treatment of these leukemias.

The test involves analyzing the patient’s genetic material to identify any mutations in the BCR-ABL1 kinase domain, providing critical information for personalized treatment planning. It is particularly valuable for patients who are experiencing resistance to TKI therapy, as it helps in selecting the most effective treatment strategy moving forward.

At DNA Labs UAE, the BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test is priced at 2200 AED. This cost reflects the sophisticated technology and expertise required to accurately detect and interpret the specific genetic mutations. For patients and healthcare providers, this test represents a crucial step in tailoring leukemia treatment to the individual’s genetic profile, potentially improving treatment outcomes and quality of life.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test

Welcome to DNA Labs UAE, a leading genetic lab offering the BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test. This test is used to detect mutations in the BCR-ABL1 gene, which is associated with chronic myeloid leukemia (CML) and certain types of acute lymphoblastic leukemia (ALL).

Test Details

The BCR-ABL1 kinase domain mutation analysis is a type of genetic testing that helps in the diagnosis and management of CML and ALL. It detects specific mutations in the BCR-ABL1 gene, which can lead to resistance to targeted therapies like tyrosine kinase inhibitors (TKIs).

Components

  • EDTA Vacutainer (2ml)

Price

The cost of the BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test is 2200.0 AED.

Sample Condition

The test requires bone marrow or peripheral blood samples. It is important to transport the samples immediately to ensure accurate results.

Report Delivery

The test results are typically delivered within 7-8 days.

Method

The BCR-ABL1 kinase domain mutation analysis is performed using Sanger Sequencing, a technique that allows for the detection of specific mutations in the BCR-ABL1 gene.

Test Type

The BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test falls under the category of Genetics.

Doctor

This test is recommended by Gynecologists.

Test Department

This test is conducted in the Genetics department.

Pre Test Information

The BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test requires a doctor’s prescription. However, it is not applicable for surgery and pregnancy cases or individuals planning to travel abroad.

Importance of BCR-ABL1 Kinase Domain Mutation Analysis

The BCR-ABL1 gene produces a protein called BCR-ABL1 kinase, which plays a critical role in the development and progression of CML and ALL. Mutations in the kinase domain of this gene can lead to resistance to targeted therapies, such as tyrosine kinase inhibitors (TKIs), which are commonly used to treat these types of leukemia.

The BCR-ABL1 kinase domain mutation analysis helps guide treatment decisions by identifying patients who may benefit from alternative therapies or dose adjustments. It is also used to monitor treatment response and assess the efficacy of targeted therapies.

Conclusion

The BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test is a vital tool in the management of CML and ALL. It helps in the early detection of mutations in the BCR-ABL1 gene, allowing for personalized treatment plans and improved patient outcomes.

Test Name BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test
Components EDTA Vacutainer (2ml)
Price 2200.0 AED
Sample Condition Bone marrow \/ Peripheral blood (Transport immediately)
Report Delivery 7-8 days
Method Sanger Sequencing
Test type Genetics
Doctor Gynecologist
Test Department:
Pre Test Information BCR-ABL1 Kinase Domain Mutation Analysis IRMA] can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

BCR-ABL1 kinase domain mutation analysis is a type of genetic testing that is used to detect mutations in the BCR-ABL1 gene. This gene is associated with chronic myeloid leukemia (CML) and certain types of acute lymphoblastic leukemia (ALL).

The BCR-ABL1 gene produces a protein called BCR-ABL1 kinase, which plays a critical role in the development and progression of CML and ALL. Mutations in the kinase domain of this gene can lead to resistance to targeted therapies, such as tyrosine kinase inhibitors (TKIs), which are commonly used to treat these types of leukemia.

The BCR-ABL1 kinase domain mutation analysis is typically performed using a technique called allele-specific polymerase chain reaction (PCR) or reverse transcription PCR (RT-PCR). This allows for the detection of specific mutations in the BCR-ABL1 gene.

The International Randomized Study of Interferon versus STI571 (IRIS) is a clinical trial that compared the efficacy of interferon-alpha and imatinib (STI571) in the treatment of newly diagnosed CML. The IRMA assay was used in this trial to monitor BCR-ABL1 kinase domain mutations and assess treatment response.

Overall, BCR-ABL1 kinase domain mutation analysis is an important tool in the management of CML and ALL, as it helps guide treatment decisions and identify patients who may benefit from alternative therapies or dose adjustments.

SKU: TEST-4837 Category:

Related products